GALECTIN THERAPEUTICS INC — Director's Dealing 2018

Jun 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-13

Reporting Person: CALLICUTT JACK W (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-12	Common Stock	M	9294	$1.37	Acquired	10554	Direct
2018-06-12	Common Stock	S	9294	$7.0117	Disposed	1260	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-11	Stock option (right to buy)	$1.37	M	9294	Disposed	2026-01-20	Common Stock (9294)	Direct

Footnotes

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018.

F2: The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.